KLF5 Inhibition Overcomes Oxaliplatin Resistance in Patient-Derived Colorectal Cancer Organoids by Restoring Apoptotic Response

Researchers constructed colorectal cancer PDOs and selected the Kruppel-like factor 5 (KLF5) inhibitor ML264 as the research object based on the results of an in vitro drug screening assay.